ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,431.60
      -0.04%
      US Tech 100
      19,168.00
      0.52%
      Dow Jones
      38,589.16
      -0.15%
      Brent Oil
      82.275
      0.00%
      Bitcoin
      66,502.00
      0.47%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Indaptus Therapeutics Inc (INDP)

      7. Indaptus Therapeutics Inc (INDP) News

      INDP

      Indaptus Therapeutics (INDP)

      Indaptus Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:INDP
      DateTimeSourceHeadlineSymbolCompany
      06/11/20248:00AMGlobeNewswire Inc.Indaptus Therapeutics to Present Positive Data on Lead Product Candidate, Decoy20, at STING & TLR-Targeted Therapies SummitNASDAQ:INDPIndaptus Therapeutics Inc
      06/07/20245:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INDPIndaptus Therapeutics Inc
      06/07/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
      06/04/20248:00AMGlobeNewswire Inc.Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
      06/03/20248:00AMGlobeNewswire Inc.Indaptus Therapeutics Announces New Positive Data from Ongoing Phase 1 Trial of Decoy20NASDAQ:INDPIndaptus Therapeutics Inc
      05/30/20248:00AMGlobeNewswire Inc.Indaptus Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
      05/29/20248:00AMGlobeNewswire Inc.Indaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
      05/22/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
      05/22/20248:00AMGlobeNewswire Inc.Indaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid TumorsNASDAQ:INDPIndaptus Therapeutics Inc
      05/08/20248:06AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INDPIndaptus Therapeutics Inc
      05/08/20248:05AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
      05/08/20248:00AMGlobeNewswire Inc.Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
      04/11/20247:30AMGlobeNewswire Inc.Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
      03/28/20248:00AMGlobeNewswire Inc.Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
      03/25/20248:30AMGlobeNewswire Inc.Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual MeetingNASDAQ:INDPIndaptus Therapeutics Inc
      03/18/20248:00AMGlobeNewswire Inc.Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024NASDAQ:INDPIndaptus Therapeutics Inc
      03/13/20247:30AMGlobeNewswire Inc.Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
      03/04/202411:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
      03/04/20247:30AMGlobeNewswire Inc.Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortNASDAQ:INDPIndaptus Therapeutics Inc
      02/15/20248:00AMGlobeNewswire Inc.Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceNASDAQ:INDPIndaptus Therapeutics Inc
      02/08/20248:00AMGlobeNewswire Inc.Indaptus Therapeutics Expands Digital Presence with Launch of Social Media ChannelsNASDAQ:INDPIndaptus Therapeutics Inc
      01/23/20244:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:INDPIndaptus Therapeutics Inc
      01/23/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
      01/04/20248:00AMGlobeNewswire Inc.European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform TechnologyNASDAQ:INDPIndaptus Therapeutics Inc
      11/06/20234:06PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:INDPIndaptus Therapeutics Inc
      11/06/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
      11/06/20234:01PMGlobeNewswire Inc.Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:INDPIndaptus Therapeutics Inc
      11/06/20238:13AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
      11/06/20238:00AMGlobeNewswire Inc.Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 StudyNASDAQ:INDPIndaptus Therapeutics Inc
      10/31/20239:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:INDPIndaptus Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:INDP

      Your Recent History

      NYSE
      PPX
      PPL Capital Funding
      Delayed Upgrade Clock